New pill targets hard-to-treat obesity after brain injury

NCT ID NCT06046443

Completed Disease control Sponsor: Rhythm Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an experimental daily pill, LB54640, in 28 people aged 12 and older with hypothalamic obesity—a condition where brain injury causes rapid, severe weight gain. For the first 14 weeks, some received the drug and some a placebo to see if it safely reduces weight and hunger. Those who finished could continue on the drug for up to a year.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPOTHALAMIC OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acquired hypothalamic obesity Sexual Infantilism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPOTHALAMIC OBESITY

Contacts and locations

Locations

Birmingham Women's and Children's NHS Foundation Trust

Birmingham, B15 2TG, United Kingdom
Children's Hospital Colorado

Aurora, Colorado, 80045, United States
Columbia University

New York, New York, 10027, United States
Great Ormond Street Hospital for Children

London, WC1N 3JH, United Kingdom
Lynn Health Science Institute

Oklahoma City, Oklahoma, 73112, United States
St. Jude Children's Research Hospital

Memphis, Tennessee, 38105, United States
The University of North Carolina at Chapel Hill

Chapel Hill, North Carolina, 27514, United States
Tufts Medical Center

Boston, Massachusetts, 02111, United States
University of Cambridge

Cambridge, CB2 1TN, United Kingdom
University of Iowa Children's Hospital

Iowa City, Iowa, 52242, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.